secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001437749-26-002799
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue
--------------------------------------------------------------------------------

- Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
- Adjusted EBITDA -$0.8M vs +$1.3M, driven by EXXUA launch investments; cash $30.0M.
- ADHD portfolio revenue $13.2M (down from $13.8M); pediatric $1.7M (down from $2.4M) due to marketing deemphasis.
- EXXUA launched Dec 2025; initial stocking revenue $0.2M; 40+ person sales force deployed targeting $22B MDD market.
- Cash and cash equivalents $30.0M, largely unchanged from $31.0M at June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926002799/0001437749-26-002799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926002799/aytu20251124_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-002799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer